| Previous Close | 34.30 |
| Open | 34.00 |
| Bid | 32.32 x 800 |
| Ask | 34.79 x 900 |
| Day's Range | 32.70 - 34.81 |
| 52 Week Range | 20.03 - 54.97 |
| Volume | 340,359 |
| Avg. Volume | 377,217 |
| Market Cap | 1.23B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.64 |
| Earnings Date | Nov. 03, 2020 - Nov. 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.38 |
- Zacks
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -2.25% and -14.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Analysts Estimate Regenxbio (RGNX) to Report a Decline in Earnings: What to Look Out for
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Regenxbio Inc Earnings Call
© 2020 Verizon Media. All rights reserved.
